Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2

Daisuke Ohki1 | Nobutake Yamamichi1 | Yoshiki Sakaguchi1 | Yu Takahashi1 | Natsuko Kageyama-Yahara1 | Mitsue Yamamichi1 | Chihiro Takeuchi1 | Yosuke Tsuji1 | Yasuhiro Sakai2 | Kouhei Sakurai2 | Shuta Tomida3 | Kazuhiko Koike1 | Mitsuhiro Fujishiro1

Abstract

The objective of this study was to elucidate the molecular background of sessile serrated adenoma/polyp (SSA/P) endoscopically resected with comprehensive gene expression analysis. Gene expression profiling was performed for 10 tumor-normal pairs of SSA/P. Cluster analysis, gene set enrichment analysis (GSEA), and consensus molecular subtype (CMS) classification of colorectal cancer (CRC) were applied to our transcriptome analysis. Unsupervised cluster analysis showed that the gene expression profile of SSA/Ps is different from that of adjacent normal epithelial cells, even in the very early stage of tumorigenesis. According to the CMS classification, our microarray data indicated that SSA/Ps were classified as CMS1. GSEA demonstrated a strong association between SSA/P and microsatellite instability-high (MSI-H) CRC ($p < 10^{-5}$). Transcriptome analysis of five MSI-related genes ($\text{MSH2, MSH6, MLH1, PMS1, and PMS2}$) and five CRC-related genes ($\text{BRAF, KRAS, APC, TP53, and CDX2}$) showed that CDX2 expression was most severely decreased in SSA/P. Immunohistochemical staining confirmed that CDX2 protein was reduced compared with the surrounding mucosa. Direct sequencing of the $\text{BRAF}$ gene showed that the $\text{BRAF V600E}$ mutation was detected in only nine of 36 cases. In a mouse model, $\text{BRAF}$, $\text{APC}$, or $\text{CDX2}$ deficiency indicated that the gene expression pattern with loss of CDX2 is more similar to our SSA/Ps compared with those induced by $\text{BRAF}$ or $\text{APC}$ mutation. Transcriptome analysis of SSA/Ps showed characteristic gene expression with a strong resemblance to MSI-H CRC. Downregulation of CDX2 expression is an essential molecular mechanism involved in the initial stage of SSA/P tumorigenesis. (UMIN000027365).

KEYWORDS

CDX2, comprehensive gene expression analysis, microsatellite instability-high colorectal cancer, sessile serrated adenoma/polyp, transcriptome analysis
1 | INTRODUCTION

Colorectal cancer (CRC) is a major cause of cancer-related deaths worldwide. Based on current understanding, CRCs are derived from three different pathways: the chromosomal instability pathway, familial pathway, and serrated pathway. Approximately 20–30% of all CRCs are derived from serrated pathways.

Serrated lesions were classified into five groups according to the World Health Organization revised in 2019: sessile serrated lesions, sessile serrated lesions with dysplasia, hyperplastic polyps (HPs), traditional serrated adenomas (TSAs), and unclassified serrated adenomas. In Japan, serrated lesions are classified into three groups according to the Japanese Classification of Colorectal Carcinoma: sessile serrated adenoma/polyps (SSA/Ps), HPs, and TSAs.

Recently, SSA/Ps have been attracting attention and are considered precursor lesions of CRC via the serrated pathway. SSA/Ps were hypothesized to have a high BRAF mutant and CpG island methylator phenotype. Some SSA/Ps then acquire microsatellite instability (MSI) through MLH1 methylation, leading to MSI-high (MSI-H) cancer, while others lead to microsatellite stable (MSS) cancer. However, the prevalence of SSA/Ps might be lower than that in tubular adenomas. A prospective study reported that the prevalence of SSA/Ps in Japan is approximately 5%. Therefore, little is known about the molecular biological background and carcinogenesis mechanisms of SSA/Ps.

Consensus molecular subtypes (CMS) have recently gained attention. CMS is a gene expression-based subtype of CRCs. CRCs are classified into four subtypes: CMS1 (microsatellite instability immune, 14%), hypermutated, microsatellite unstable, and strong immune activation; CMS2 (canonical, 37%), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic, 13%), epithelial and evident metabolic dysregulation; CMS4 (mesenchymal, 23%), prominent transforming growth factor-β activation, stromal invasion, and angiogenesis. Treatment responsiveness and prognosis differ depending on the type of CMS.

In this context, we investigated the molecular biological background of SSA/Ps through a bioinformatic analysis of comprehensive gene expression and performed CMS classification of SSA/Ps using the obtained gene expression profiles. Furthermore, based on transcriptome analysis, we investigated the molecular mechanism of the very early stages of SSA/P tumorigenesis.

2 | METHODS

2.1 | Patients

This study was a prospective, single-center study. Patients with SSA/P who underwent endoscopic resection at the University of Tokyo Hospital between June 2017 and September 2018, were enrolled. All patients were endoscopically or pathologically diagnosed with SSA/P before enrollment. The following patients were excluded: a past medical history of lower gastrointestinal surgery, comorbid malignant disease, familial polyposis, inflammatory bowel disease, ethical considerations, and not being diagnosed with SSA/P pathologically. Written informed consent was obtained from all the patients. Formalin-fixed paraffin-embedded samples of 39 endoscopically resected SSA/Ps at our institute were also collected retrospectively for histochemical analysis.

This study was approved by the Research Ethics Committee of the Graduate School of Medicine and Faculty of the University of Tokyo and registered in the University Hospital Medical Network Clinical Trial Registry (UMIN000027365).

2.2 | Sample preparation

Specimens were obtained from the tumor and paired with the surrounding mucosa through endoscopic biopsy immediately before resection of the target lesions using endoscopic biopsy forceps (Radial Jaw 4 PEDIATRIC 2.0 mm; Boston Scientific). The samples were immediately placed in Eppendorf tubes with RNAlater (Thermo Fisher Scientific, San Diego, CA, USA) and stored at room temperature for several hours before storing at −80°C. The SSA/Ps were endoscopically resected after biopsy and pathologically evaluated after formalin fixation. The resected tissues were re-evaluated using endoscope photographs and pathological specimens.

2.3 | RNA isolation and quality check (QC)

Specimens were homogenized using a Power Masher (Nippi Inc.) with BioMasher II (Nippi Inc.) in QIAzol Lysis Reagent (Qiagen). Total RNA was extracted using the miRNeasy Mini Kit (Qiagen). Quantity and purity (A260/280 ratio, A260/A230 ratio) of the extracted RNA were measured using a NanoDrop1000 spectrometer (NanoDrop Technologies). Quality check of extracted RNA was performed by measuring RNA Integrity Number and the 28S/18S rRNA ratio using an Agilent 2100 BioAnalyzer (Agilent Technologies).

2.4 | Gene expression profiling

Oligonucleotide microarray (Agilent SurePrint G3 Human Gene Expression 8×60k v3; Agilent, Inc.) was
performed using 10 SSA/P-normal pairs, followed by fluorescence assessment using a microarray scanner D (Agilent Technologies, Inc.). Raw data were logged (base2) and quantile normalization was performed using the Gene Spring software (Agilent Technologies). Raw data are registered in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE198692.

### 2.5 | Gene expression analysis and cluster analysis

Average linkage hierarchical clustering of both genes and cases was performed using median centering and normalization with Cluster 3.0 (http://rana.lbl.gov/EisenSoftware.htm). The results were displayed using TreeView software (http://rana.lbl.gov/EisenSoftware.htm).

### 2.6 | CMS classification

Classification of gene expression profiles of SSA/Ps into the four CMSs of CRC was performed using pre-validated multiplatform analysis packages: CMS classifier (https://github.com/Sage-Bionetworks/CMSclassifier)\(^\text{18}\) and CMS caller (https://github.com/Lothelab/CMScaller).\(^\text{20}\)

### 2.7 | Direct Sanger sequencing for BRAF

Genomic DNA was extracted from tissue samples using MagMAX™ FFPE DNA/RNA Ultra Kit (Thermo Fisher Scientific, Wilmington, DE, USA) according to the manufacturer’s instructions. BRAF exon 15 was amplified by PCR using the forward primer sequence 5’-TCATAATGCTGCTCTGATAGGA-3’ and the reverse primer sequence 5’-GCGCCAAATTTAATCAGTGG-3’ to yield an amplicon size of 224 bp. The PCR mix contained 1x PCR Buffer for KOD FX Neo, 0.4 mM dNTPs, 0.3 μM primers, 0.5 U KOD FX Neo (TOYOBO, Osaka, Japan), and 1 μl DNA template in a total reaction volume of 25 μl. The PCR cycling conditions were as follows: 94°C for 2 min, 45 cycles of denaturation at 98°C for 10 s, annealing at 60°C for 30 s, and extension at 68°C for 30 s with a final extension at 68°C for 7 min. PCR products were loaded on an agarose gel, and the band corresponding to the BRAF exon-15 fragment was excised from the gel and purified using a QIAGEN QIAquick gel extraction kit (Qiagen, Hilden, Germany). PCR products (20 ng) were used as templates for sequencing. Sequences were outsourced, and the products were analyzed by Fasmac Japan (Kanagawa, Japan).

### 2.8 | Evaluation of CDX2 expression in SSA/P by immunohistochemical staining

To examine the expression of CDX2 proteins, immunohistochemical staining was performed on 39 SSAP samples, three melanoma samples, and three advanced CRC samples. Two micrometer thick sections of formalin-fixed embedded samples were deparaffinized. Antigen activation treatment was performed at 95°C for 20 min using citrate buffer (Code.RM102-C; LSI medience). The sections were washed with running water and immersed in TBS. Primary immunostaining with CDX2 (CMC235R14RUO-0.1Ml; cosmobi.co.jp) at a 1:200 dilution was applied for 60 min at room temperature. Sections were then incubated with the secondary amino acid polymer reagent Histofine Simple Stain MAX PO (414154F; Nichirei Biosciences) for 30 min at room temperature. The reaction products were visualized by incubating the sections in a 20 mg/dL 3,3′-diaminobenzidine tetrahydrochloride solution containing 0.006% H₂O₂ for 5 min. The immunostained sections were evaluated and scored by two expert pathologists.

### 2.9 | GSEA of SSA/P

The gene expression profile of our SSA/Ps was compared with the gene expression profile of the mucosa of the colon of mice obtained from GSE84650 of the GEO series\(^\text{21}\) using Gene Set Enrichment Analysis (GSEA 4.1.0) (http://software.broadinstitute.org/gsea/). The gene expression profiles obtained from mice were as follows: a) CDX2 null mutant colon epithelium, b) BRAF V600E mutant colon epithelium, c) CDX2 null / BRAF V600E mutant colon epithelium, and d) APC mutant colon epithelium, and normal colon epithelium. GSE84650 uses GPL17400 as the platform; therefore, the HUGO Gene Nomenclature Committee (https://www.genenames.org/) was used to convert the mouse gene symbol into a human gene symbol. Using the gene expression profile converted to the human gene symbol, each mutant colon epithelium was compared with the normal colon mucosa.

Each gene set, such as (a) [Ohki mouse CDX2-], (b) [Ohki mouse BRAF-], (c) [Ohki mouse CDX2-/BRAF-], and (d) [Ohki mouse APC-], was made by genes that were elevated compared with the normal colon. Four gene sets were included in the pre-validated curated C2 gene set database, GSEA was performed using the gene expression profile of SSA/P obtained from the present microarray.

GSEA was then performed to analyze genes with differences in expression between tumor and paired surrounding mucosa and to characterize SSA/P by comparing the obtained gene sets to known disease-related gene sets,
especially the pre-validated curated C2 gene set database. The [OHKI SSAP UP] gene set comprised 100 genes that were most prominently upregulated in SSA/P compared with the surrounding normal mucosa. The [OHKI SSAP DOWN] gene set was made of 100 genes that most prominently downregulated gene transcripts in SSA/P compared with the surrounding normal mucosa. Two gene sets were included in the pre-validated curated C2 gene set database, and cross-reference gene enrichment analysis between SSA/P, adenoma, and MSI-H CRC was performed.

2.10 Biological pathway analysis

Biological pathway analysis was performed to determine functional gene ontology terms specific to tumors and paired surrounding mucosa using DAVID Bioinformatics Resources 6.7 (http://david.ncifcrf.gov/home.jsp).

3 RESULTS

3.1 Patient characteristics

A total of 32 cases and the surrounding mucosa were prospectively accumulated during the study period. Four cases were excluded, which were not pathologically diagnosed as SSA/P, and 28 SSA/P cases were finally included in the analysis (Figure 1A). The baseline characteristics of SSA/Ps are shown in Table S1. 67.8% (19/28) were female and 89.3% (25/28) of SSA/P lesions were located in the proximal colon. Of the 28 cases enrolled, total RNA was extracted from 14 tumors and the surrounding mucosa, in which 10 cases that passed the quality check of RNA were used for microarray gene expression analysis and bioinformatic analysis.

3.2 Gene expression analysis and cluster analysis

Comprehensive gene expression was evaluated, and 50 gene transcripts most prominently upregulated and downregulated in SSA/Ps (compared with the surrounding normal mucosa) are shown in Tables 1 and 2. Various genes previously reported to increase transcription have been detected, including ANXA10, TM4SM4, VSIG1, SULT1C2, CDH3, KLK7, TFF2, REG4, SERPINB5, KLK11, MUC5AC, TFF1, MUC17, CTSE, CLDN1, and S100P. The top 500 gene transcripts upregulated and downregulated in SSA/Ps are also shown in Tables S2 and S3.

We then identified the gene probes satisfying the criterion of mean + 3 standard deviations (SD) and performed an unsupervised cluster analysis. A total of 694 gene probes were satisfied mean + 3SD from 58,201 total probes. We created a cluster tree with these identified 694 gene probes and found that the tumor and normal mucosa were separated clearly (Figure 1B). These data indicate that the transcriptome profile of SSA/P is quite different from that of adjacent normal epithelial cells, even in the very early stage of its tumorigenesis.

3.3 CMS classification of CRC

CMS classification was performed using comprehensive gene expression profiles of 10 SSA/Ps using the CMS Classifier and CMS caller. The CMS classifier showed that 70% (7/10) of SSA/Ps were classified as CMS1 (Figure 2A). The CMS caller indicated that 90% (9/10) of SSA/Ps were classified as CMS1 (Figure 2B). As a result, CMS classification analyses indicated that SSA/P is highly associated with CMS1; namely, most of the analyzed SSA/Ps were categorized as CMS1.

FIGURE 1 Flowchart and results of gene expression analysis between matched SSA/P and normal mucosa. (A) Flowchart of study UMIN000027365. (B) A hierarchical cluster tree of the unsupervised analysis for 694 probes satisfying the mean + 3SD from all 58,201 probes.
| Rank | Gene symbol | Ave. of tumor | Ave. of normal | Folds |
|------|-------------|---------------|----------------|-------|
| 1    | ANXA10      | 11.87         | 1.97           | 9.90  |
| 2    | TM4SF4      | 12.14         | 2.77           | 9.38  |
| 3    | VSIG1       | 10.80         | 2.25           | 8.55  |
| 4    | KLK8        | 9.75          | 1.78           | 7.97  |
| 5    | SEMG1       | 8.95          | 1.65           | 7.31  |
| 6    | SULT1C2     | 10.35         | 3.13           | 7.22  |
| 7    | CDH3        | 9.99          | 2.80           | 7.20  |
| 8    | GJB4        | 9.66          | 2.54           | 7.13  |
| 9    | KLK7        | 8.59          | 1.49           | 7.11  |
| 10   | TFF2        | 13.80         | 6.71           | 7.09  |
| 11   | REG4        | 14.83         | 8.19           | 6.64  |
| 12   | EPHX4       | 8.81          | 2.21           | 6.60  |
| 13   | FOXD1       | 8.43          | 2.17           | 6.25  |
| 14   | GJB5        | 8.29          | 2.04           | 6.25  |
| 15   | MUC6        | 7.78          | 1.55           | 6.23  |
| 16   | DPCR1       | 7.93          | 1.74           | 6.19  |
| 17   | SERPINB5    | 13.23         | 7.25           | 5.98  |
| 18   | SLC6A14     | 8.53          | 2.57           | 5.96  |
| 19   | TRIM29      | 9.71          | 3.89           | 5.81  |
| 20   | DUOXA2      | 11.23         | 5.43           | 5.80  |
| 21   | KLK11       | 11.09         | 5.29           | 5.80  |
| 22   | ALDOB       | 11.99         | 6.30           | 5.70  |
| 23   | CLDN2       | 9.13          | 3.48           | 5.65  |
| 24   | PSCA        | 10.99         | 5.35           | 5.64  |
| 25   | MUC5AC      | 9.33          | 3.73           | 5.60  |
| 26   | TFF1        | 17.58         | 11.98          | 5.59  |
| 27   | MUC17       | 14.16         | 8.59           | 5.57  |
| 28   | HTR1D       | 7.37          | 1.82           | 5.55  |
| 29   | TCN1        | 7.75          | 2.24           | 5.50  |
| 30   | TACSTD2     | 10.69         | 5.20           | 5.49  |
| 31   | FOXQ1       | 11.27         | 5.82           | 5.45  |
| 32   | SH3PXD2A-AS1| 10.13         | 4.70           | 5.42  |
| 33   | CTSE        | 14.21         | 8.84           | 5.37  |
| 34   | LOC101927318| 7.12          | 1.79           | 5.33  |
| 35   | CLDN18      | 7.01          | 1.73           | 5.27  |
| 36   | Inc-NUCB1-1 | 13.08         | 7.81           | 5.27  |
| 37   | KLHL30      | 7.21          | 1.97           | 5.24  |
| 38   | VNN1        | 10.64         | 5.41           | 5.23  |
| 39   | FAM25A      | 7.51          | 2.30           | 5.21  |
| 40   | NR0B2       | 8.80          | 3.61           | 5.19  |
| 41   | CRNDE       | 8.65          | 3.51           | 5.14  |
| 42   | Inc-SIK1-2  | 8.65          | 3.55           | 5.10  |
| 43   | CA9         | 6.74          | 1.64           | 5.10  |

Table 1: Top 50 most prominently upregulated gene transcripts in SSA/P compared with the surrounding normal mucosa.
3.4 | Expression of MSI-associated genes and CRC-related genes

Based on the results of CMS classification, we focused on the genes associated with MSI, such as \( MSH2 \), \( MSH6 \), \( MLH1 \), \( PMS1 \), and \( PMS2 \), using the gene expression profiles of our SSA/Ps. We also focused on \( BRAF \), \( KRAS \), \( APC \), \( TP53 \), and \( CDX2 \), which are established cancer-related genes important for colorectal tumorigenesis. 26–31

Figure 3 shows the expression ratio of each gene in tumor tissues compared with that in normal tissues. The expression ratio of MSI-related genes in tumor tissues was not significantly different from that in normal tissues (expression ratio: \( MSH2 0.96, MSH6 0.95, MLH1 1.06, PMS1 0.97, PMS2 0.78 \)). On the contrary, many cancer-related genes tended to show decreased expression in tumor tissues (expression ratio: \( BRAF 0.74, KRAS 0.70, APC 0.82, TP53 1.10 \)). Although mutation is a well-known mechanism of oncogenesis for \( BRAF \), \( KRAS \), \( APC \), and \( TP53 \), our data showed that transcription was slightly decreased for \( BRAF \), \( KRAS \), and \( APC \) (Figure 3). Among the 10 genes, the expression ratio of \( CDX2 \) was the most severely decreased (expression ratio: 0.44). The expression level of \( CDX2 \) was considerably lower in the tumor tissue than in the normal tissue in all 10 cases.

3.5 | Direct Sanger sequencing for \( BRAF \)

Next, we analyzed the sequence of the \( BRAF \) gene since mutations in \( BRAF \) (especially \( BRAF V600E \)) have been most frequently reported in SSA/P. 32–35 Direct Sanger sequencing was performed for 38 SSA/P lesions. Two cases were excluded because of failed PCR due to the low quality of the extracted DNA. Of the 36 cases evaluated, the \( BRAF V600E \) mutation was found in nine cases. Direct Sanger sequencing indicated that 25.0% (9/36) of SSA/Ps had the \( BRAF V600E \) mutation.

3.6 | Evaluation of \( CDX2 \) expression in SSA/P by immunohistochemistry

Of the various CRC-related genes, our results showed that \( CDX2 \) expression was severely decreased in tumor tissues compared with that in normal tissues (Figure 3). To confirm whether the protein level of \( CDX2 \) was decreased in SSA/Ps, immunohistochemical staining was performed on 39 cases of SSA/P. As shown in Figure 4, immunohistochemical staining clearly showed a remarkable reduction in \( CDX2 \) protein expression in the very early stages of SSA/P, all of which were endoscopically resected. The immunohistochemistry staining of \( CDX2 \) in 39 SSA/P samples was summarized in Table S5, in which the staining rate in SSA/P tumors was shown in comparison with the staining rate of surrounding normal colorectal mucosa.

3.7 | Comparison of comprehensive gene expression between our SSA/Ps and a mouse model deficient in \( BRAF \), \( APC \), or \( CDX2 \) genes

Our analyses revealed that \( CDX2 \) expression was severely decreased in early-stage SSA/Ps (Figures 3 and 4). In addition, our results also indicated that the expression and function of \( BRAF \) and \( APC \) may be diminished (Figure 3), although the mutation of the \( BRAF \) gene was not as frequent (25.0%). To confirm these results in silico, we compared them with mRNA transcription data of animal models deficient in \( BRAF \), \( APC \), or \( CDX2 \) (GSE84650). 21 GSEA C2 curated with the four gene sets from GSE84650.
| Rank | Gene symbol | Ave. of tumor | Ave. of normal | Folds |
|------|-------------|---------------|---------------|-------|
| 1    | CWH43       | 5.74          | 10.21         | −4.46 |
| 2    | SSTR2       | 3.58          | 8.04          | −4.46 |
| 3    | CA1         | 10.29         | 14.40         | −4.11 |
| 4    | DPP10-AS1   | 4.93          | 9.00          | −4.06 |
| 5    | CHGA        | 10.48         | 14.50         | −4.02 |
| 6    | TRPM6       | 7.79          | 11.73         | −3.93 |
| 7    | CLDN8       | 3.47          | 7.23          | −3.76 |
| 8    | LOC102723970| 2.69          | 6.35          | −3.66 |
| 9    | HSPB3       | 4.74          | 8.39          | −3.65 |
| 10   | PDE6A       | 6.00          | 9.60          | −3.60 |
| 11   | BMP3        | 5.00          | 8.60          | −3.60 |
| 12   | GCG         | 6.32          | 9.91          | −3.58 |
| 13   | HTR4        | 4.50          | 8.08          | −3.58 |
| 14   | NUPR1L      | 4.18          | 7.65          | −3.48 |
| 15   | NEUROD1     | 2.92          | 6.34          | −3.42 |
| 16   | SLC26A2     | 12.09         | 15.49         | −3.40 |
| 17   | CLCA1       | 11.93         | 15.33         | −3.40 |
| 18   | CD177       | 9.47          | 12.86         | −3.39 |
| 19   | SATB2-AS1   | 7.60          | 10.96         | −3.36 |
| 20   | UGT2A3      | 4.14          | 7.49          | −3.34 |
| 21   | LOC100422737| 4.01          | 7.32          | −3.31 |
| 22   | XLOC\_l2\_009159| 4.00 | 7.31 | −3.31 |
| 23   | AQP8        | 9.54          | 12.84         | −3.29 |
| 24   | lnc-NR3C2–1 | 2.04          | 5.30          | −3.25 |
| 25   | BEST4       | 8.80          | 12.04         | −3.24 |
| 26   | SLC6A4      | 3.45          | 6.68          | −3.23 |
| 27   | WISP2       | 3.60          | 6.82          | −3.22 |
| 28   | SLC30A10    | 6.51          | 9.65          | −3.14 |
| 29   | EYA2        | 3.45          | 6.56          | −3.11 |
| 30   | TMIGD1      | 8.48          | 11.57         | −3.10 |
| 31   | ASPG        | 4.67          | 7.76          | −3.09 |
| 32   | lnc-LYRM7-2 | 4.62          | 7.70          | −3.08 |
| 33   | CHGB        | 3.35          | 6.41          | −3.06 |
| 34   | LOC101927969| 3.12          | 6.17          | −3.05 |
| 35   | BEST2       | 8.15          | 11.18         | −3.02 |
| 36   | lnc-SOD3-3  | 5.85          | 8.85          | −3.01 |
| 37   | OGDHL       | 2.92          | 5.91          | −2.99 |
| 38   | ADH1C       | 11.69         | 14.66         | −2.97 |
| 39   | lnc-VCAN-1  | 2.75          | 5.71          | −2.96 |
| 40   | BRINP3      | 4.67          | 7.63          | −2.96 |
| 41   | INS L5      | 3.70          | 6.65          | −2.96 |
| 42   | MT1H        | 8.38          | 11.34         | −2.95 |
| 43   | KANK4       | 2.55          | 5.50          | −2.95 |
showed that the correlation with the gene expression profile of our SSA/P was higher in the order of [Ohki mouse CDX2-] (Enrichment score 0.667, $p < 10^{-5}$), [Ohki mouse CDX2-/BRAF-] (Enrichment score 0.553, $p < 10^{-5}$), [Ohki mouse BRAF-] (Enrichment score 0.507, $p = 0.008$), and [Ohki mouse APC-] (Enrichment score 0.469, $p = 0.004$) (Figure 5A). These results indicate that decreased expression of CDX2 considerably influences the molecular biology of the early stage of SSA/P tumorigenesis.

### GSEA for SSA/P

GSEA to classify the gene expression of SSA/Ps using the pre-verified C2 curated gene set database showed that 265 gene sets were significantly upregulated in SSA/Ps ($p < 0.05$), whereas 12 gene sets were down-regulated in SSA/Ps ($p < 0.05$). The top 10 gene sets upregulated in SSA/Ps are shown in Figure 5B, together with ES (enrichment score) and normalized
enrichment score (NES). Various gene sets concerning tumorigenesis, epithelial differentiation/regeneration, oncogene-related, etc. were identified. Among them, the top three gene sets deserved our attention as follows. [HINATA_NFKB_TARGETS_KERATINOCYTE_DN] (genes downregulated in primary keratinocytes by expression of p50 and p65 components of NFkB) was the most significantly correlated gene set for upregulation (Enrichment score 0.865, \( p = 0.004 \)). In this gene set, 39.1% (9/23) of genes were four times higher in SSA/Ps than in the surrounding normal mucosa. [SABATES_COLORECTAL_ADENOMA] was the gene set from the colorectal adenoma reported by Sabates et al., which consists of genes upregulated in colorectal adenoma compared with surrounding normal mucosa (Enrichment score 0.846, \( p < 10^{-5} \)). [WATANABE_COLON_CANCER_MSI_VS_MSS_UP] was the gene set derived from MSI-high CRC reported by Watanabe et al., which comprises genes upregulated in MSI-high CRC compared with MSS CRC (Enrichment score 0.826, \( p < 10^{-5} \)). The specimens were obtained from advanced CRCs resected surgically, except for familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer.

We applied our two gene sets, [OHKI SSAP UP] and [OHKI SSAP DOWN], into GSEA C2 curated, and cross-reference analysis was performed with adenoma and MSI-high CRC (Table S4). Our analyses indicated that gene
expression of SSA/P was significantly associated with MSI-H CRCs but not with colorectal adenomas.

3.9 Biological pathway analysis

The DAVID pathway analysis was performed using 360 probes. These probes were selected to demonstrate a twofold difference in expression between all matched tumor-normal pairs (320 upregulated and 40 downregulated). The functional classifications upregulated in tumors are shown in Table S6. "Annexin V" was the most upregulated in the tumors. Many genes such as "Secreted" and "Signal," which were correlated with secretion inside and outside the cell, were included. In contrast, no functional classification was detected that was significantly downregulated in tumors (Table S7).

4 DISCUSSION

In this study, we performed comprehensive gene expression analysis by microarray using the very early stages of SSA/P tumors. Some reports have described the transcriptome analysis of SSA/Ps in Western countries. However, to the best of our knowledge, this is the first study to investigate the comprehension of bioinformatic analysis in East Asia. Based on the very high level of endoscopic therapy in Japan, all the analyzed SSA/P tumors were in the initial stages of tumorigenesis. CMS classification by CMS Classifier and CMS caller demonstrated that SSA/Ps are classified as CMS1. These results suggest that SSA/Ps can progress to MSI-H CRCs. With reference to gene sets actually used in CMS caller, the notable upregulated gene sets of CMS1 are "MSI-high" and "cell cycle." On the contrary, inactivated gene sets of CMS1 include "CDX2," "intestinal differentiation," and "LGR5." "MSI-high" gene set should reflect the identified "WATANABE_COLON_CANCER_MSI_VS_MSS_UP" showing the similarity with SSA/P (Figure 5B). Previous reports have also suggested that SSA/Ps might progress to MSI-H CRCs based on the analysis of limited specific genes. However, to the best of our knowledge, this is the first study to investigate the comprehension of bioinformatic analysis in East Asia. Based on the very high level of endoscopic therapy in Japan, all the analyzed SSA/P tumors were in the initial stages of tumorigenesis.
our present study, we clearly showed that a decrease of CDX2 occurs in the very early stage of SSA/P tumorigenesis (Figure 4). Considering all these, we think it is reasonable that SSA/P is categorized into CMS1.

This is the first study from East Asia, where the prevalence and character of gastrointestinal disease were quite different from Western countries. It has been reported that when MLH1 deletion is added to SSA/P, it acquires heteromorphism and progresses to MSH-H CRC. Therefore, we evaluated the expression levels of genes associated with MSI (MSH2, MSH6, MLH1, PMS1, and PMS2) or CRC (BRAF, KRAS, APC, TP53, and CDX2). Our transcriptome analysis showed that some of them, including BRAF and APC, were mildly decreased, but direct Sanger sequencing of the BRAF gene showed a mutation rate (BRAF V600E) of 25%, which was less than that previously reported. We also found that CDX2 showed the lowest expression ratio in tumor tissues compared with normal tissues, which was verified by immunohistochemical staining.

Furthermore, GSEA using animal models (GSE84650) showed that gene expression patterns induced by loss of CDX2 were more similar to those of our SSA/Ps, compared with those induced by BRAF or APC mutations. Some reports also showed decreased expression of CDX2 in SSA/Ps, and it has also been reported that decreased expression of CDX2 correlates with BRAF V600E mutation and the serrated pathway. CDX2 is a well-known master gene essential for intestinal development, differentiation, and maintenance of function. Therefore, we speculate that decreased expression of CDX2 plays an important role in the very early stages of SSA/P tumorigenesis.

GSEA also showed that SSA/P has a gene expression profile with a strong correlation to MSI-H CRC and tubular adenoma. Previously, it was thought that SSA/Ps might have different characteristics from tubular adenomas, but our results suggest that SSA/Ps and tubular adenomas might have similar gene expression profiles. On the contrary, cross-reference analysis showed that SSA/Ps were correlated with MSI-H CRCs, but tubular adenomas were not correlated with MSI-H CRCs.

We acknowledge that there are several limitations to our study. First, the subjects of comprehensive gene expression in this study were only SSA/Ps. In the serrated pathway, microvesicular HPs (MVHPs) are thought to be precursor lesions of SSA/Ps, and SSA/Ps acquire MSI accumulation of DNA methylation leading to MSI-H CRCs via SSA/P with cytological dysplasia. If comprehensive gene expression analysis of each MVHP, SSA/Ps with cytological dysplasia, and MSI-H cancers can be performed, it might be possible to obtain results approaching the mechanism of oncogenesis by comparing with the results of SSA/Ps in this study. However, the prevalence of SSA/Ps with cytological dysplasia is very low, and detection of SSA/Ps with cytological dysplasia is difficult. Furthermore, the dysplastic area of SSA/Ps with cytological dysplasia did not occupy the entire lesion, and it is difficult to correctly obtain endoscopic biopsy specimens from dysplastic areas based on endoscopic findings. We should compare SSA/Ps, SSA/Ps with cytological dysplasia, and MSI-H CRCs and confirm whether SSA/Ps progress to MSI-H CRCs. Second, the cases of SSA/Ps in which we performed comprehensive gene analysis were scarce. Third, we use the name “SSA/P” in this study. In 2019, the revision of the WHO classification changed the name of SSA/P to SSL. Strictly speaking, these two are not identical, but we think our results from SSA/P can mostly apply to understanding SSL based on the similarity of SSA/P and SSL. In fact, the name “SSA/P” is still widely used in the world. Fourth, we believe that it is necessary to investigate the Beta-catenin localization and ERK-phosphorylation in order to evaluate the functional effects of the changes in APC and BRAF transcript levels. We would like to make this an issue for future study.

In conclusion, our study demonstrates that the gene expression profiles of SSA/Ps are strongly correlated with those of MSI-H CRCs and that downregulation of CDX2 expression is essential for the first step in the tumorigenesis of SSA/P.

**AUTHOR CONTRIBUTIONS**

Conception and design: Daisuke Ohki, Nobutake Yamamichi, Shuta Tomida. Development of methodology: Daisuke Ohki, Nobutake Yamamichi, Yoshiki Sakaguchi, Yu Takahashi, Natsuko Kageyama-Yahara, Mitsue Yamamichi, Chihiro Takeuchi. Data analysis and interpretation: Daisuke Ohki, Nobutake Yamamichi, Yoshiki Sakaguchi, Shuta Tomida, Natsuko Kageyama-Yahara, Mitsue Yamamichi, Yasuhiro Sakai, Kouhei Sakurai. Writing, review, and/or revision of the manuscript: Daisuke Ohki, Nobutake Yamamichi, Yoshiki Sakaguchi, Shuta Tomida, Chihiro Takeuchi, Natsuko Kageyama-Yahara, Mitsue Yamamichi, Yasuhiro Sakai, Kouhei Sakurai, Yosuke Tsuji, Kazuhiko Koike and Mitsuhiro Fujishiro.

**ACKNOWLEDGMENTS**

This work was supported by JSPS KAKENHI Grant Number JP20K16980. The authors thank Shinya Kodashima, Satoshi Ono, Kazushi Fukagawa, Naoki Tamura, and Yoko Miura for their assistance as participating investigators in the acquisition of samples.
CONFLICT OF INTEREST
All authors have no conflict of interest.

DATA AVAILABILITY STATEMENT
Raw data are registered in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession number GSE198692.

ETHICAL APPROVAL STATEMENT
This study was approved by the Research Ethics Committee of the Graduate School of Medicine and Faculty of the University of Tokyo (review number: 11537-1).

CLINICAL TRIAL REGISTRATION NUMBER
This study was registered in the University Hospital Medical Network Clinical Trial Registry (UMIN000027365).

INFORMED CONSENT
Written informed consent was obtained from all the patients.

ORCID
Nobutake Yamamichi https://orcid.org/0000-0002-5741-9887

REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
2. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059-2072.
3. Vasen HF, Mösllein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007;44:353-362.
4. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107: 1315–1329; quiz 1314, 1330.
5. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1-10.
6. Ahadi M, Sokolova A, Brown I, Chou A, Gill AJ. The 2019 World Health Organization classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment. Pathology. 2021;53:454-461.
7. Yao T, Sugai T, Iwashita A, et al. Histopathological characteristics and diagnostic criteria of SSA/P: project research “potential of cancerization of colorectal serrated lesions” of Japanese Society for Cancer of the colon and Rectum. Stomach Intest 2011; 46: 442–448 (in Japanese with English abstract).
8. Kahi CJ. How does the serrated polyp pathway alter CRC screening and surveillance? Dig Dis Sci. 2015;60:773-780.
9. Cappellessro L, Lo Mele M, Munari G, et al. Molecular characterization of “sessile serrated” adenoma to carcinoma transition in six early colorectal cancers. Pathol Res Pract. 2019;215:957-962.
10. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62:367-386.
11. De Sousa E, Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19:614-618.
12. Zorzi M, Senore C, Da Re F, et al. Detection rate and predictive factors of sessile serrated polyps in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPe study (evaluating quality indicators of the performance of endoscopy). Gut. 2016;66:1233-1240.
13. Ross WA, Thirumurthi S, Lynch PM, et al. Detection rates of premalignant polyps during screening colonoscopy: time to revise quality standards? Gastrointest Endosc. 2015;81:567-574.
14. Ilseepert JE, de Wit K, van der Vlugt M, Bastiaansen BA, Fockens P, Dekker E. Prevalence, distribution and risk of sessile serrated adenomas/polyps at a center with a high adenoma detection rate and experienced pathologists. Endoscopy 2016; 48: 740–746.
15. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Gastrointest Endosc. 2017;86:18-33.
16. Rotondano G, Bianco MA, Cipolletta L, Marro M, Serrated LESions of the COlorectum (SELCO) investigators. Prevalence and characteristics of serrated lesions of the colorectum in Italy: a multicentre prospective cohort study. Dig Liver Dis. 2015;47:512-517.
17. Sano W, Sano Y, Iwatate M, et al. Prospective evaluation of the proportion of sessile serrated adenoma/polyps in endoscopically diagnosed colorectal polyps with hyperplastic features. Endosc Int Open. 2015;3:E354-E358.
18. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350-1356.
19. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79-92.
20. Eide PW, Bruun J, Lothe RA, Sveen A. CMScaler: an R package for consensus molecular subtyping of colorectal cancer preclinical models. Sci Rep. 2017;7:16618.
21. Sakamoto N, Fung Y, Stolfi C, Kurosu Y, Green M, Lin J, Green ME, Sentani K, Yasui W, McMahon M, Hardiman KM, Spence JR, Horita N, Greenson JK, Kuick R, Cho KR, Fearon ER BRAF Elife 2017; 6, BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis, 6.
22. Caruso M, Moore J, Goodall GJ, et al. Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. Virchows Arch. 2009;454:291-302.
23. Gonzalez DH, Lai KK, Shadrach B, et al. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyyp. J Pathol. 2013;230:420-429.
24. Delker DA, McGettigan BM, Kanth P, et al. RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS One. 2014;9:e88367.
25. Kanth P, Bronner MP, Boucher KM, et al. Gene signature in sessile serrated polyps identifies colon cancer subtype. Cancer Prev Res (Phila). 2016;9:456-465.
26. Wu JM, Montgomery EA, Iacobuzio-Donahue CA. Frequent beta-catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential. *Am J Clin Pathol*. 2008;129:416-423.

27. Dawson H, Galván JA, Helbling M, et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. *Int J Cancer*. 2014;134:2342-2351.

28. Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. *N Engl J Med*. 2016;374:211-222.

29. Saito T, Niida A, Uchi R, et al. A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. *Nat Commun*. 2018;9:2884.

30. Chan DKH, Buczacki SJA. Tumour heterogeneity and evolutionary dynamics in colorectal cancer. *Oncogenesis*. 2021;10:53.

31. Cross W, Kovac M, Mustonen V, et al. The evolutionary landscape of colorectal tumorigenesis. *Nat Ecol Evol*. 2018;2:1661-1672.

32. Inoue A, Okamoto K, Fujino Y, et al. B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P. *Br J Cancer*. 2015;112:403-412.

33. Patai Á, Barták BK, Péterfia B, et al. Comprehensive DNA methylation and mutation analyses reveal a methylation signature in colorectal sessile serrated adenomas. *Pathol Oncol Res*. 2016;23:589-594.

34. Dehghanizadeh S, Khoddami V, Mosbruger TL, et al. Active BRAF-V600E is the key player in generation of a sessile serrated polyp-specific DNA methylation profile. *PLoS One*. 2018;13:e0192499.

35. Erlenbach-Wünsch K, Bihl M, Hartmann A, Groisman GM, Vieth M, Agaimy A. Serrated epithelial colorectal polyps (hyperplastic polyps, sessile serrated adenomas) with perineurial stroma: clinicopathological and molecular analysis of a new series. *Ann Diagn Pathol*. 2018;35:48-52.

36. Sabates-Bellver J, Van der Flier LG, de Palo M, et al. Transcriptome profile of human colorectal adenomas. *Mol Cancer Res*. 2007;5:1263-1275.

37. Watanabe T, Kobunai T, Toda E, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. *Cancer Res*. 2006;66:9804-9808.

38. Liu C, Walker NI, Leggett BA, Whitehall VL, Bettington ML, Rosty C. Sessile serrated adenomas with dysplasia: morphological patterns and correlations with MLH1 immunohistochemistry. *Mod Pathol*. 2017;30:1728-1738.

39. Mochizuka A, Uehara T, Nakamura T, Kobayashi Y, Ota H. Hyperplastic polyps and sessile serrated 'adenomas' of the colon and rectum display gastric pyloric differentiation. *Histochim Cell Biol*. 2007;128:445.

40. Guo RJ, Suh ER, Lynch JP. The role of cdx proteins in intestinal development and cancer. *Cancer Biol Ther*. 2004;3:593-601.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Ohki D, Yamamichi N, Sakaguchi Y, et al. Transcriptome of sessile serrated adenoma/polyp is associated with MSI-high colorectal cancer and decreased expression of CDX2. *Cancer Med*. 2022;11:5066-5078. doi: [10.1002/cam4.4810](https://doi.org/10.1002/cam4.4810)